Clinical study of daunomycin (NSC-82151) in children with acute leukemia

✍ Scribed by Charlene P. Holton; Chairman Derrick Lonsdale; Audrey H. Nora; William G. Thurman; Teresa J. Vietti

• Publisher: John Wiley and Sons
• Year: 1968
• Tongue: English
• Weight: 290 KB
• Volume: 22
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(196811)22:5<1014::aid-cncr2820220517>3.0.co;2-f

✦ Synopsis

Thirty-nine children with advanced leukemia, resistant to conventional chemotherapy, were treated with daunomycin. Seven patients (18%) achieved partial or complete marrow remissions within a median time of 17 days. Five of the seven children who responded received prednisone concurrently. The remissions lasted only 21-37 days. Limiting toxicity included leukopenia, thrombocytopenia, and oral ulcerations. No renal, hepatic, or cardiac toxicity was noted. It is concluded that daunomycin alone has low-grade activity for induction of remission in children with advanced acute leukemia and that combinat i o n with prednisone may enhance the response rate.

HE PEDIATRIC DIVISION OF T H E SOUTHWEST

T Cancer Chemotherapy Study Group has studied the effect of daunomycin (NSC-82151) in the management of advanced acute leukemia in children. T h e study is based on the known activity of the drug in untreated leukemia in children5. 0 and on studies in leukemia L-1210 in mice showing no cross resistance with conventional agents, such as methotrexate, mercaptopurine, and cyclophosph ;t mi tle .